Skip to main content

PEGSITACIANINE FOR THE SURGICAL DETECTION OF HEAD AND NECK CANCER


PURPOSE
To investigate whether Pegsitacianine a fluorescent nanoparticle can image head and neck cancer and unknown primary head and neck cancer during surgery or biopsy.

INCLUSION

  1. Adults greater than or equal to 18 years of age
  2. Patients with stage 1-4 Head and Neck Squamous Cell Carcinoma (HNSCC) undergoing surgical excision

DESIGN

  1. Phase 2 Clinical trial of Pegsitacianine, which is not yet FDA approved, for fluorescent imaging of primary tumors and metastatic lymph nodes in patients with head and neck cancer
  2. Efficacy of Pegsitacianine for detecting unknown primary head and neck cancers

RESEARCH COORDINATOR
Phone: 214-648-5051
Email: OTOResearch@UTSouthwestern.edu

LOCATION
UT Southwestern Medical Center
Baran D. Sumer, M.D., F.A.C.S.
Professor of Otolaryngology- Head and Neck Surgery
2001 Inwood Road, 7th Floor
Dallas, Texas, 75235

For more details refer to https://clinicaltrials.gov/ Identifier: NCT05576974

For more information, contact Research team at OTOresearch@utsouthwestern.edu